{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-082897","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2026-07-13T12:30:43+00:00","discovered_at":"2026-07-13T12:35:00.481191+00:00","generated_at":"2026-07-13T12:35:14.982453+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocugen signs binding term sheet with Roots Pharmaceutical to license OCU400 in MENA; up to $255M milestones, 22% royalty","bullets":["Upfront and near-term development milestones up to $4M; sales milestones up to $255M.","Ocugen to receive 22% royalty on net sales of OCU400 in MENA region.","Definitive license agreement expected within 90 days; Ocugen to manufacture supply.","OCU400 is a modifier gene therapy for retinitis pigmentosa, a leading cause of inherited vision loss."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-082897","json":"https://secwatch.observer/filing/0001104659-26-082897.json","markdown":"https://secwatch.observer/filing/0001104659-26-082897.md","text":"https://secwatch.observer/filing/0001104659-26-082897.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926082897/0001104659-26-082897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926082897/tm2620295d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-13T12:35:14.982453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}